Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company headquartered in Salt Lake City, Utah, with news flow centered on silicon nitride–based medical technologies, implant systems, and infection‑prevention platforms. This news page aggregates company press releases and third‑party coverage so readers can follow developments in its silicon nitride biomaterials, polymer composites, and antipathogenic fabric technologies.
Recent SINTX news highlights regulatory milestones and product launches, including U.S. FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System and the launch of OsseoSculpt, a biologic designed to complement the SINAPTIC wedge portfolio. Updates also cover the company’s focused commercialization plan around infection‑resistant silicon nitride devices and polymer composites, as well as early product revenue from OsseoSculpt.
Investors and industry observers will find coverage of strategic agreements, such as the supply agreement with EVONIK to manufacture SINTX’s proprietary SiN/PEEK compound for AI‑assisted, 3D‑printed, patient‑specific implants. News items also track SINTX’s intellectual‑property progress, including Notices of Allowance from the United States Patent and Trademark Office for composition and method patents covering antipathogenic fibrous materials and fabric technologies.
In addition, SINTX issues releases on capital markets activity and corporate events, including warrant exercises, at‑the‑market offering arrangements, and participation in investor conferences hosted by firms such as H.C. Wainwright and Sidoti & Company. These updates provide context on the company’s financing strategy and investor outreach.
By monitoring this page, readers can review SINTX news related to medical device clearances, biologic product introductions, infection‑prevention patents, financing transactions, and investor presentations, all in one place.
SINTX Technologies, Inc. (NASDAQ: SINT) has announced a registered direct offering involving the sale of 1,500,000 shares of common stock at $2.00 per share for gross proceeds of approximately $3.0 million. The offering is set to close around July 21, 2020, contingent on customary conditions. Maxim Group LLC is acting as the sole placement agent. The shares are offered under an effective shelf registration statement filed with the SEC. The funds are expected to support the company's operations and development of silicon nitride ceramics for various applications.
SINTX Technologies has announced its compliance with NASDAQ's minimum bid price requirements for continued listing. This follows a notice from NASDAQ indicating that SINTX's common stock closed at or above $1.00 for at least ten consecutive business days, from June 22 to July 8, 2020. The matter concerning Listing Rule 5550(a)(2) is now resolved. SINTX focuses on manufacturing and developing silicon nitride ceramics for various applications, bolstered by its FDA-registered and ISO 13485 certified facility.
SINTX Technologies, Inc. (NASDAQ: SINT) announced a registered direct offering of 3,700,000 shares at $1.50 each, raising approximately $5.6 million. The offering is set to close around June 25, 2020, pending customary conditions. Maxim Group LLC is the sole placement agent. This issuance is part of a previously filed shelf registration statement under SEC rules. The funds raised will likely support SINTX's ongoing development of silicon nitride applications in various sectors.
SINTX Technologies (NASDAQ: SINT) announced promising preliminary results from a controlled study showing that their sintered silicon nitride powder inactivates the SARS-CoV-2 virus. The findings align with known antibacterial properties of silicon nitride and efficacy against similar viruses. CEO Dr. Sonny Bal emphasized ongoing independent testing to validate these results. SINTX is dedicated to rigorous R&D verification. However, they caution investors against assuming commercial effectiveness until further data is available.